Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicole Hartmann

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Epilepsia|December 9, 2022
Spike patterns surrounding sleep and seizures localize the seizure-onset zone in focal epilepsyErin C Conrad, Andrew Y Revell, Adam S Greenblatt, et al.
Cancer Research|March 19, 2009
Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrowTanja Nicole Hartmann, Valentin Grabovsky, Wei Wang, et al.
Clinical and Translational Medicine|May 19, 2015
Gene expression profiling of immunomagnetically separated cells directly from stabilized whole blood for multicenter clinical trialsMartin Letzkus, Evert Luesink, Sandrine Starck-Schwertz, et al.
Oncotarget|April 21, 2015
CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21Sylvia Ganghammer, Evelyn Hutterer, Elisabeth Hinterseer, et al.
Annals of Hematology|June 5, 2018
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Annals of Hematology|June 24, 2018
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Cancer Research Communications|April 10, 2024
Modeling Myeloma Dissemination In Vitro with hMSC-interacting Subpopulations of INA-6 Cells and Their Aggregation/Detachment DynamicsMartin Kuric, Susanne Beck, Doris Schneider, et al.
Frontiers in Oncology|July 3, 2025
Leveraging a foundation model zoo for cell similarity search in oncological microscopy across devicesGabriel Kalweit, Anusha Klett, Paula Silvestrini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2023
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor TherapyAnfal Alsadhan, Jonathan Chen, Erika M Gaglione, et al.
Leukemia|February 23, 2020
TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemiaEva Szenes, Andrea Härzschel, Sarah Decker, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Epilepsia|December 9, 2022
Spike patterns surrounding sleep and seizures localize the seizure-onset zone in focal epilepsyErin C Conrad, Andrew Y Revell, Adam S Greenblatt, et al.
Cancer Research|March 19, 2009
Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrowTanja Nicole Hartmann, Valentin Grabovsky, Wei Wang, et al.
Clinical and Translational Medicine|May 19, 2015
Gene expression profiling of immunomagnetically separated cells directly from stabilized whole blood for multicenter clinical trialsMartin Letzkus, Evert Luesink, Sandrine Starck-Schwertz, et al.
Oncotarget|April 21, 2015
CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21Sylvia Ganghammer, Evelyn Hutterer, Elisabeth Hinterseer, et al.
Annals of Hematology|June 5, 2018
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Annals of Hematology|June 24, 2018
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Cancer Research Communications|April 10, 2024
Modeling Myeloma Dissemination In Vitro with hMSC-interacting Subpopulations of INA-6 Cells and Their Aggregation/Detachment DynamicsMartin Kuric, Susanne Beck, Doris Schneider, et al.
Frontiers in Oncology|July 3, 2025
Leveraging a foundation model zoo for cell similarity search in oncological microscopy across devicesGabriel Kalweit, Anusha Klett, Paula Silvestrini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2023
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor TherapyAnfal Alsadhan, Jonathan Chen, Erika M Gaglione, et al.
Leukemia|February 23, 2020
TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemiaEva Szenes, Andrea Härzschel, Sarah Decker, et al.
Pageof 9